The iShares Global Healthcare ETF (ASX: IXJ) gives Australians exposure to the world’s largest healthcare companies — the pharmaceutical giants, biotechnology innovators, medical-device makers and health insurers that underpin global healthcare. As a sector, healthcare is often prized for combining defensive characteristics with long-term growth, driven by ageing populations and medical innovation.

In September 2026, with markets volatile and investors weighing defensive Options alongside growth, healthcare is back in focus, and IXJ is a leading way to access it on the ASX. This article explains how IXJ works, why it is in focus, and the catalysts and risks that could shape it from here.

What is the IXJ ETF?

IXJ is a passive ETF issued by BlackRock under its iShares brand. It aims to provide the performance of a global healthcare index — having tracked the S&P Global 1200 Health Care Index and, following an index change in March 2026, an updated S&P global healthcare benchmark — before fees and expenses. The fund provides exposure to global companies in the healthcare sector, charges a management fee of around 0.40% per annum, is currency-unhedged, and has been listed on the ASX since 2001.

Because it follows a global healthcare index, IXJ is dominated by large US healthcare companies, with additional exposure to Europe and other developed markets. Its holdings span pharmaceuticals, biotechnology, medical devices and equipment, healthcare providers and insurers. The index applies caps to limit concentration in the very largest companies. Healthcare is often considered a defensive sector because Demand for medical care is relatively stable through the economic cycle, while innovation and demographics provide Long-term Growth — a combination sometimes described as defensive growth.

What is driving interest now?

Healthcare’s appeal rests on its dual character. On one hand, it is defensive: people need medical care regardless of the economic cycle, giving the sector relatively stable demand. On the other, it offers long-term growth, driven by ageing populations in developed markets, rising healthcare spending, and continual innovation in drugs, devices and treatments. In volatile or uncertain markets, investors often look to defensive sectors like healthcare for relative stability.

Several near-term themes are also in focus. Innovation in areas such as weight-loss and obesity drugs, biotechnology and medical technology has driven strong performance among some healthcare companies. At the same time, the sector faces policy and pricing scrutiny, particularly in the United States, where drug pricing and healthcare policy are perennial issues. The interplay of defensive demand, innovation-driven growth and policy risk shapes how healthcare — and IXJ — performs. For Australian investors, the unhedged currency exposure adds a further variable.

Portfolio and holdings

IXJ’s portfolio is dominated by the world’s largest healthcare companies, overwhelmingly US-based, with the index capping the aggregate weight of the very largest names to limit concentration. Its holdings span the major global pharmaceutical companies, leading biotechnology firms, medical-device and equipment makers, and large health insurers and providers. The largest positions are typically the biggest global drugmakers and healthcare conglomerates.

This composition gives IXJ broad exposure across the healthcare value chain. Pharmaceuticals and biotechnology drive much of the innovation and growth, medical-device makers benefit from technological advances, and insurers and providers are tied to healthcare systems and policy. The Diversification across sub-sectors means IXJ is less dependent on any single company than a narrow fund, though it remains concentrated in the healthcare sector and in the United States, so US healthcare policy is a significant influence.

Catalysts to watch

Several factors could influence IXJ in the coming months: US healthcare policy and drug-pricing developments, a key source of risk; innovation in areas such as obesity drugs, biotechnology and medical technology; the defensive appeal of healthcare during any market volatility; ageing-population and healthcare-spending trends; and the AUD/USD Exchange Rate for unhedged returns.

Risks

IXJ carries risks specific to sector investing. Policy and Regulatory Risk is significant, particularly US drug-pricing and healthcare-policy developments, which can move the sector. Sector-concentration risk means IXJ depends on healthcare rather than the broad market. Country concentration in the United States is a feature. Currency risk is unhedged. Single-company risk applies to the largest holdings, including drug-approval and patent-expiry risks. Market Risk applies. While healthcare is often defensive, it can still underperform for extended periods and is exposed to specific sector risks.

Outlook

IXJ offers Australians diversified exposure to global healthcare, a sector that blends defensive characteristics with long-term growth from demographics and innovation. Its near-term fortunes rest on healthcare policy, innovation trends and the sector’s defensive appeal in volatile markets. Investors may be watching US drug-pricing policy, biotechnology and medical-technology innovation, and the Australian dollar for direction. The outlook may depend on whether defensive growth reasserts itself and on how policy and pricing developments unfold, particularly in the United States.